Research Growth, AI Licensing, and Cost Reduction Drive Wiley's Fiscal 2025 Results
HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) today reported results for the fourth quarter and fiscal year ended April 30, 2025.
FISCAL 2025 HIGHLIGHTS
GAAP performance vs. prior year: Operating Income of $221 million vs. $52 million and Diluted Earnings Per Share (EPS) of $1.53 vs. ($3.65)
Exceeded Adjusted EPS guidance, delivered at top end of range for Adjusted EBITDA margin, and achieved Free Cash Flow outlook
Delivered Revenue and Adjusted EBITDA margin growth in both Research and Learning segments
Achieved Adjusted Operating Margin expansion of 300 basis points
Executed AI content licensing project this quarter with a third large tech company; $40 million in total AI licensing revenue realized in Fiscal 2025 compared to $23 million in Fiscal 2024
Drove a 34% increase in share repurchases and raised dividend for 31 st consecutive year
MANAGEMENT COMMENTARY
'We delivered another strong year of execution as we met or exceeded our financial commitments, drove profitable growth in our core, expanded margins and free cash flow, and extended further into the corporate market through AI licensing and partnership, science analytics, and knowledge services,' said Matthew Kissner, President and CEO. 'Our multi-year journey of continuous improvement and innovation is yielding material gains in profitable revenue growth, margin expansion, and cash generation, and we remain steadfast and confident in our continued progress.'
FINANCIAL SUMMARY
Please see accompanying financial tables for more detail.
Q4 reported revenue of $443 million vs. $468 million due to foregone revenue from divestitures; Adjusted Revenue (excluding divestitures) essentially even with prior year at constant currency as expected; Research Publishing +4% constant currency.
Q4 Operating Income of $76 million vs. $69 million; Adjusted Operating Income +15% with margin up 260bps. Diluted EPS of $1.25 vs. $0.46; Adjusted EPS +14% and Adjusted EBITDA essentially even.
Full year reported revenue of $1,678 million vs. $1,873 million due to foregone revenue from divested businesses; Adjusted Revenue (excluding divestitures) +3% at constant currency.
Full year Operating Income of $221 million vs. $52 million; Adjusted Operating Income +29% with margin up 300 basis points. Diluted EPS of $1.53 vs. ($3.65); Adjusted EPS +31% to $3.64, Adjusted EBITDA +8% to $398 million, and Cash from Operations of $203 million vs. $208 million; Free Cash Flow +10% to $126 million.
RESEARCH
Q4 Research revenue of $281 million was up 4% as reported and 3% at constant currency driven by solid growth in recurring revenue publishing models (calendar year 2025 journal renewals) and open access offsetting continued softness in backfiles, archives, and other ancillary products. Q4 Adjusted EBITDA of $97 million was up 4% as reported and at constant currency due to revenue growth. Adjusted EBITDA margin for the quarter rose modestly to 34.7%.
Full year Research revenue was up 3% as reported and at constant currency driven by growth in publishing and solutions. Research Adjusted EBITDA was up 4% or 5% at constant currency with margin up 30 basis points to 32.1%. Key performance indicators remained strong for the year, with submissions up 19% and output up 8%.
LEARNING
Q4 Learning revenue of $162 million was down 5% as reported and at constant currency as expected due to a $23 million AI licensing agreement in the prior year, partially offset by growth in Academic and additional AI licensing revenue this quarter. Academic growth excluding AI licensing was driven by strong demand for inclusive access and digital courseware. Professional performance excluding AI licensing was impacted by retail channel softness. Q4 Adjusted EBITDA of $70 million for the quarter was down 6% as reported and at constant currency due to lower revenues. Adjusted EBITDA margin was 43.0% compared to 43.5% in prior year period.
Full year Learning revenue of $585 million was up 2% as reported and at constant currency driven by growth in Academic and AI licensing. Learning Adjusted EBITDA of $219 million for the year was up 9% as reported and at constant currency. Adjusted EBITDA margin rose 250 basis points to 37.4%.
CORPORATE EXPENSES
'Corporate Expenses' are the portion of shared services costs not allocated to segments.
Q4 Corporate Expenses declined by 8% or 7% at constant currency due to lower depreciation and amortization, or 3% on an Adjusted EBITDA basis at constant currency due to restructuring savings.
Full year Corporate Expenses declined by 3% as reported and at constant currency due to lower depreciation and amortization, but rose 2% on an Adjusted EBITDA basis at constant currency due to enterprise modernization.
BALANCE SHEET, CASH FLOW, AND CAPITAL ALLOCATION
Net Debt-to-EBITDA Ratio was 1.8 compared to 1.7 in the year-ago period.
Net Cash provided by Operating Activities was $203 million compared to $208 million primarily due to spend on cloud-based solutions related to targeted enterprise modernization work. This spend is capitalized and amortized, like capex, but reported in this section of the cash flow statement. Otherwise, cash flow benefited from higher adjusted EBITDA and favorable working capital movements.
Free Cash Flow was up 10% to $126 million primarily driven by lower capex. Fiscal 2025 capex was $77 million vs. $93 million in prior year, however, capitalization between the two years were comparable when capex and cloud-based solution spend are combined.
Returns to Shareholders: Wiley allocated $137 million toward dividends and share repurchases, up from $122 million in the prior year. $60 million was allocated to share repurchases at an average cost basis of $44.16. This allocation is up from $45 million in the prior year period.
Divestiture Proceeds: After the year closed, Wiley received $120 million in cash proceeds related to the University Services divestiture, with the total outstanding note paid in full.
Adjusted Revenue – growth expectation driven by demand to publish and Calendar Year 2025 journal renewal growth in Research Publishing, steady market trends in Academic, and continued demand for our content and data in AI development, partially offset by large AI agreements in prior year.
Adjusted EBITDA Margin – initial margin target was a range of 24 to 25% (January 2024). Wiley raised the target to 25%+ in March 2025, and this quarter to a range of 25.5% to 26.5%. Outlook is driven by anticipated cost savings, efficiency gains, and revenue growth.
Adjusted EPS – growth expectation driven by higher expected Adjusted Operating Income.
Free Cash Flow – growth outlook driven by expected Adjusted EBITDA growth, lower restructuring payments, and favorable working capital.
EARNINGS CONFERENCE CALL
Scheduled for today, June 17 at 10:00 am (ET). Access webcast at Investor Relations at investors.wiley.com, or directly at https://events.q4inc.com/attendee/978555203. U.S. callers, please dial (888) 210-3346 and enter the participant code 2521217#. International callers, please dial (646) 960-0253 and enter the participant code 2521217#.
ABOUT WILEY
Wiley (NYSE: WLY) is one of the world's largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We enable knowledge-seekers to transform today's biggest obstacles into tomorrow's brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com and investors.wiley.com.
NON-GAAP FINANCIAL MEASURES
Wiley provides non-GAAP financial measures and performance results such as 'Adjusted EPS,' 'Adjusted Operating Income,' 'Adjusted EBITDA,' 'Adjusted Income before Taxes,' 'Adjusted Income Tax Provision,' 'Adjusted Effective Income Tax Rate,' 'Free Cash Flow less Product Development Spending,' 'organic revenue,' 'Adjusted Revenue,' and results on a Constant Currency basis to assess underlying business performance and trends. Management believes non-GAAP financial measures, which exclude the impact of restructuring charges and credits and certain other items, and the impact of divestitures and acquisitions provide a useful comparable basis to analyze operating results and earnings. See the reconciliations of non-GAAP financial measures and explanations of the uses of non-GAAP measures in the supplementary information. We have not provided our 2026 outlook for the most directly comparable U.S. GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with U.S. GAAP.
FORWARD-LOOKING STATEMENTS
This release contains certain forward-looking statements concerning the Company's operations, performance, and financial condition. Reliance should not be placed on forward-looking statements, as actual results may differ materially from those in any forward-looking statements. Any such forward-looking statements are based upon a number of assumptions and estimates that are inherently subject to uncertainties and contingencies, many of which are beyond the control of the Company and are subject to change based on many important factors. Such factors include, but are not limited to: (i) the level of investment in new technologies and products; (ii) subscriber renewal rates for the Company's journals; (iii) the financial stability and liquidity of journal subscription agents; (iv) the consolidation of book wholesalers and retail accounts; (v) the market position and financial stability of key online retailers; (vi) the seasonal nature of the Company's educational business and the impact of the used book market; (vii) worldwide economic and political conditions; (viii) the Company's ability to protect its copyrights and other intellectual property worldwide (ix) the ability of the Company to successfully integrate acquired operations and realize expected opportunities; (x) the ability to realize operating savings over time and in fiscal year 2026 in connection with our multiyear Global Restructuring Program and completed dispositions; (xi) cyber risk and the failure to maintain the integrity of our operational or security systems or infrastructure, or those of third parties with which we do business; (xii) as a result of acquisitions, we have and may record a significant amount of goodwill and other identifiable intangible assets and we may never realize the full carrying value of these assets; and (xiii) other factors detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events.
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
Revenue, net
$
442,579
$
468,461
$
1,677,609
$
1,872,987
Costs and expenses:
Cost of sales
110,941
123,345
431,380
579,722
Operating and administrative expenses
229,767
252,062
947,437
1,013,520
Impairment of goodwill (3)
-
-
-
108,449
Restructuring and related charges
12,490
11,008
25,561
63,041
Amortization of intangible assets
12,909
13,264
51,822
55,994
Total costs and expenses
366,107
399,679
1,456,200
1,820,726
Operating income
76,472
68,782
221,409
52,261
As a % of revenue
17.3
%
14.7
%
13.2
%
2.8
%
Interest expense
(11,270
)
(11,411
)
(52,547
)
(49,003
)
Net foreign exchange transaction (losses) gains
(826
)
530
(8,142
)
(2,959
)
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (3)
(13,580
)
(3,642
)
(23,340
)
(183,389
)
Other income (expense), net
1,469
(257
)
5,498
(3,957
)
Income (loss) before taxes
52,265
54,002
142,878
(187,047
)
(Benefit) provision for income taxes
(15,828
)
28,737
58,717
13,272
Effective tax rate
-30.3
%
53.2
%
41.1
%
-7.1
%
Net income (loss)
$
68,093
$
25,265
$
84,161
$
(200,319
)
As a % of revenue
15.4
%
5.4
%
5.0
%
-10.7
%
Earnings (loss) per share
Basic
$
1.27
$
0.46
$
1.56
$
(3.65
)
Diluted (4)
$
1.25
$
0.46
$
1.53
$
(3.65
)
Weighted average number of common shares outstanding
Basic
53,683
54,591
54,054
54,945
Diluted (4)
54,458
55,356
54,830
54,945
Notes:
(1) The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
(2) All amounts are approximate due to rounding.
(3) Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale
For the three months and year ended April 30, 2025 and 2024, we recorded net pretax (loss) gain on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows:
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
Wiley Edge
$
(74
)
$
1,275
$
(14,852
)
$
(19,401
)
University Services
(13,428
)
(5,636
)
(12,578
)
(107,048
)
CrossKnowledge
(78
)
719
4,119
(55,440
)
Tuition Manager
-
-
120
(1,500
)
Sale of assets
-
-
(149
)
-
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale
$
(13,580
)
$
(3,642
)
$
(23,340
)
$
(183,389
)
As previously announced in fiscal year 2024, we executed a plan to divest non-core businesses included in our Held for Sale or Sold segment, including University Services, Wiley Edge, and CrossKnowledge. These three businesses met the held-for-sale criteria starting in the first quarter of fiscal year 2024. We measured each disposal group at the lower of carrying value or fair value less costs to sell prior to its disposition.
On January 1, 2024, we completed the sale of University Services. On June 5, 2025, Wiley entered into an agreement to sell the Seller Note, the fiscal year 2026 earnout, the TVG Investment, and agreed on the fiscal year 2025 earnout for total cash consideration of $119.5 million, which was fully paid in June 2025. In the year ended April 30, 2025, due to the process of selling these assets, as well as third-party customer consents, working capital adjustments, and changes in the costs to sell, we recognized an additional net loss on sale and impairments of assets of $12.6 million. In the three months ended April 30, 2025, we recognized an additional net loss of $13.4 million.
On May 31, 2024, we completed the sale of Wiley Edge, with the exception of its India operations which sold on August 31, 2024. Upon the completion of the sale, we recognized a net loss of $14.9 million in the year ended April 30, 2025 primarily due to subsequent changes in the fair value less costs to sell including reducing the fair value of the contingent consideration in the form of an earnout from $15.0 million to zero in the third quarter of fiscal year 2025, partially offset by the sale of the India operations.
On August 31, 2024, we completed the sale of CrossKnowledge. On May 31, 2023, we completed the sale of Tuition Manager.
In the second quarter of fiscal year 2025, we sold a facility which was reflected in Technology, property, and equipment, net in our Unaudited Condensed Consolidated Statements of Financial Position.
Impairment of goodwill
In fiscal year 2024, we reorganized our segments and recorded pretax noncash goodwill impairments of $108.4 million which included $81.7 million related to Wiley Edge, $11.4 million related to University Services, and $15.3 million related to CrossKnowledge.
(4) In calculating diluted net loss per common share for the year ended April 30, 2024, our diluted weighted average number of common shares outstanding excludes the effect of unvested restricted stock units and other stock awards as the effect was antidilutive. This occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive.
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1) (2)
RECONCILIATION OF US GAAP MEASURES to NON-GAAP MEASURES
(unaudited)
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
US GAAP Earnings (Loss) Per Share - Diluted
$
1.25
$
0.46
$
1.53
$
(3.65
)
Adjustments:
Impairment of goodwill
-
-
-
1.90
Restructuring and related charges
0.14
0.16
0.36
0.85
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3)
(0.01
)
0.01
0.08
0.02
Amortization of acquired intangible assets (4)
0.15
0.02
0.76
0.68
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5)
0.18
0.04
0.38
2.81
Held for Sale or Sold segment Adjusted Net (Income) Loss (5)
-
(0.03
)
0.05
(0.42
)
Income tax adjustments
(0.34
)
0.55
0.48
0.54
EPS impact of using weighted-average dilutive shares for adjusted EPS calculation (6)
-
-
-
0.05
Non-GAAP Adjusted Earnings Per Share - Diluted
$
1.37
$
1.21
$
3.64
$
2.78
Reconciliation of US GAAP Income (Loss) Before Taxes to Non-GAAP Adjusted Income Before Taxes
(amounts in thousands)
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
US GAAP Income (Loss) Before Taxes
$
52,265
$
54,002
$
142,878
$
(187,047
)
Pretax Impact of Adjustments:
Impairment of goodwill
-
-
-
108,449
Restructuring and related charges
12,490
11,008
25,561
63,041
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3)
-
815
5,590
1,903
Amortization of acquired intangible assets (4)
12,908
13,324
51,864
57,874
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5)
13,580
3,642
23,340
183,389
Held for Sale or Sold segment Adjusted (Income) Loss Before Taxes (5)
-
(2,409
)
3,578
(30,661
)
Non-GAAP Adjusted Income Before Taxes
$
91,243
$
80,382
$
252,811
$
196,948
Reconciliation of US GAAP Income Tax (Benefit) Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate
US GAAP Income Tax (Benefit) Provision
$
(15,828
)
$
28,737
$
58,717
$
13,272
Income Tax Impact of Adjustments (7)
Impairment of goodwill
-
255
-
2,953
Restructuring and related charges
4,633
2,425
5,947
15,662
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3)
571
471
1,170
582
Amortization of acquired intangible assets (4)
4,720
11,459
10,231
20,127
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5)
3,715
1,197
2,368
26,908
Held for Sale or Sold segment Adjusted Tax (Provision) Benefit (5)
-
(622
)
807
(7,140
)
Income Tax Adjustments
Impact of valuation allowance on the US GAAP effective tax rate (8)
18,776
(30,249
)
(26,008
)
(30,249
)
Impact of change in certain US state tax rates in 2025 (8)
(117
)
-
(117
)
-
Non-GAAP Adjusted Income Tax Provision
$
16,470
$
13,673
$
53,115
$
42,115
US GAAP Effective Tax Rate
-30.3
%
53.2
%
41.1
%
-7.1
%
Non-GAAP Adjusted Effective Tax Rate
18.1
%
17.0
%
21.0
%
21.4
%
Notes:
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
(2) All amounts are approximate due to rounding.
(3) In fiscal year 2023 due to the closure of our operations in Russia, the Russia entity was deemed substantially liquidated. The formal liquidation was completed in the fourth quarter of fiscal year 2025. In the three months and year ended April 30, 2025, we wrote off an additional $1.1 million and $1.4 million, respectively, of cumulative translation adjustments in earnings. In the three months and year ended April 30, 2024, we wrote off an additional $0.2 million and $1.0 million, respectively, of cumulative translation adjustments in earnings. These amounts are reflected in Net foreign exchange transaction (losses) gains on our Condensed Consolidated Statements of Net Income (Loss).
(4) Reflects the amortization of intangible assets established on the opening balance sheet for an acquired business. This includes the amortization of intangible assets such as developed technology, customer relationships, tradenames, etc., which is reflected in the "Amortization of intangible assets" line in the Condensed Consolidated Statements of Net Income (Loss). It also includes the amortization of acquired product development assets, which is reflected in Cost of sales in the Condensed Consolidated Statements of Net Income (Loss).
(5) For the three months and year ended April 30, 2025 and 2024, we recorded net pretax loss (gain) on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows:
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
Wiley Edge
$
74
$
(1,275
)
$
14,852
$
19,401
University Services
13,428
5,636
12,578
107,048
CrossKnowledge
78
(719
)
(4,119
)
55,440
Tuition Manager
-
-
(120
)
1,500
Sale of assets
-
-
149
-
Net pretax loss on sale of businesses, assets, and impairment charges related to assets held-for-sale
$
13,580
$
3,642
$
23,340
$
183,389
For the three months and year ended April 30, 2025 and 2024, we recorded income tax benefit (provision) on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows:
Three Months Ended
April 30, Year Ended
April 30,
2025
2024
2025
2024
Wiley Edge
$
263
$
890
$
(1,054
)
$
890
University Services
3,109
307
3,109
25,643
CrossKnowledge
344
-
344
-
Tuition Manager
-
-
(30
)
374
Sale of assets
-
-
-
-
Benefit on sale of businesses, assets, and impairment charges related to assets held-for-sale
$
3,715
$
1,197
$
2,368
$
26,908
In addition, our Adjusted EPS excludes the Adjusted Net Income or Loss of our Held for Sale or Sold segment.
(6) Represents the impact of using diluted weighted-average number of common shares outstanding (55.7 million for the year ended April 30, 2024) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive.
(7) For the three months and year ended April 30, 2025 and 2024, respectively, substantially all of the tax impact was from deferred taxes.
(8) In fiscal year 2024, due to temporary differences in the US, our deferred taxes reversed from a net deferred tax liability position to a net deferred tax asset position. Due to losses in the US resulting from impairments, restructuring, and acceleration of amortization expense on capitalized software, we concluded it was more-likely-than-not that all or a portion of our deferred tax asset may not be realized. As a result, we established a valuation allowance of $30.2 million. During fiscal year 2025 we increased this valuation allowance by $26.0 million, because of an increase in the US net deferred tax asset attributable primarily to interest expense disallowance and intangible and fixed assets. In connection with the increase in certain US state tax apportionment factors and state rate changes in 2025, we recorded income tax expense of $0.1 million for the three months and year ended April 30, 2025.
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1)
(unaudited)
Three Months Ended Year Ended
April 30, April 30,
2025
2024
2025
2024
Net Income (Loss)
$
68,093
$
25,265
$
84,161
$
(200,319
)
Interest expense
11,270
11,411
52,547
49,003
(Benefit) provision for income taxes
(15,828
)
28,737
58,717
13,272
Depreciation and amortization
36,681
47,613
147,126
176,989
Non-GAAP EBITDA
100,216
113,026
342,551
38,945
Impairment of goodwill
-
-
-
108,449
Restructuring and related charges
12,490
11,008
25,561
63,041
Net foreign exchange transaction losses (gains)
826
(530
)
8,142
2,959
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale
13,580
3,642
23,340
183,389
Other (income) expense, net
(1,469
)
257
(5,498
)
3,957
Held for Sale or Sold segment Adjusted EBITDA (2)
-
(2,409
)
3,578
(32,148
)
Non-GAAP Adjusted EBITDA
$
125,643
$
124,994
$
397,674
$
368,592
Adjusted EBITDA Margin
28.4
%
28.3
%
24.0
%
22.8
%
Notes:
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1) (2)
SEGMENT RESULTS
(in thousands)
(unaudited)
% Change
Three Months Ended
April 30, Favorable
(Unfavorable)
2025
2024
Reported Constant Currency
Research:
Revenue, net
Research Publishing
$
243,061
$
233,455
4
%
4
%
Research Solutions
37,660
37,577
0
%
0
%
Total Revenue, net
$
280,721
$
271,032
4
%
3
%
Non-GAAP Adjusted Operating Income
$
75,168
$
68,282
10
%
10
%
Depreciation and amortization
22,303
25,513
13
%
13
%
Non-GAAP Adjusted EBITDA
$
97,471
$
93,795
4
%
4
%
Adjusted EBITDA margin
34.7
%
34.6
%
Learning:
Revenue, net
Academic
$
100,146
$
98,908
1
%
1
%
Professional
61,712
71,237
-13
%
-14
%
Total Revenue, net
$
161,858
$
170,145
-5
%
-5
%
Non-GAAP Adjusted Operating Income
$
58,715
$
57,682
2
%
1
%
Depreciation and amortization
10,948
16,358
33
%
33
%
Non-GAAP Adjusted EBITDA
$
69,663
$
74,040
-6
%
-6
%
Adjusted EBITDA margin
43.0
%
43.5
%
Held for Sale or Sold:
Total Revenue, net
$
-
$
27,284
# #
Non-GAAP Adjusted Operating Income
$
-
$
2,409
# #
Depreciation and amortization
-
-
# #
Non-GAAP Adjusted EBITDA
$
-
$
2,409
# #
Adjusted EBITDA margin
0.0
%
8.8
%
Corporate Expenses:
Non-GAAP Adjusted Corporate Expenses
$
(44,921
)
$
(48,583
)
8
%
7
%
Depreciation and amortization
3,430
5,742
40
%
40
%
Non-GAAP Adjusted EBITDA
$
(41,491
)
$
(42,841
)
3
%
3
%
Consolidated Results:
Revenue, net
$
442,579
$
468,461
-6
%
-6
%
Less: Held for Sale or Sold Segment (3)
-
(27,284
)
# #
Adjusted Revenue, net
$
442,579
$
441,177
0
%
0
%
Operating Income
$
76,472
$
68,782
11
%
11
%
Adjustments:
Restructuring charges
12,490
11,008
-13
%
-13
%
Held for Sale or Sold Segment Adjusted Operating Income (3)
-
(2,409
)
# #
Non-GAAP Adjusted Operating Income
$
88,962
$
77,381
15
%
15
%
Adjusted Operating Income margin
20.1
%
17.5
%
Depreciation and amortization
36,681
47,613
23
%
23
%
Less: Held for Sale or Sold Segment depreciation and amortization (3)
-
-
# #
Non-GAAP Adjusted EBITDA
$
125,643
$
124,994
1
%
0
%
Adjusted EBITDA margin
28.4
%
28.3
%
Notes:
(1) The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
(2) All amounts are approximate due to rounding.
(3) Our Adjusted Revenue, Adjusted Operating Income and Adjusted EBITDA excludes the impact of our Held for Sale or Sold segment Revenue, Adjusted Operating Income or Loss and Adjusted EBITDA results.
# Variance greater than 100%
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1) (2)
SEGMENT RESULTS
(in thousands)
(unaudited)
% Change
Year Ended
April 30, Favorable
(Unfavorable)
2025
2024
Reported Constant Currency
Research:
Revenue, net
Research Publishing
$
922,553
$
892,784
3
%
3
%
Research Solutions
152,906
149,921
2
%
2
%
Total Revenue, net
$
1,075,459
$
1,042,705
3
%
3
%
Non-GAAP Adjusted Operating Income
$
255,580
$
237,763
7
%
8
%
Depreciation and amortization
89,302
93,422
4
%
5
%
Non-GAAP Adjusted EBITDA
$
344,882
$
331,185
4
%
5
%
Adjusted EBITDA margin
32.1
%
31.8
%
Learning:
Revenue, net
Academic
$
333,693
$
323,541
3
%
3
%
Professional
251,075
251,198
0
%
0
%
Total Revenue, net
$
584,768
$
574,739
2
%
2
%
Non-GAAP Adjusted Operating Income
$
174,850
$
142,733
23
%
22
%
Depreciation and amortization
43,900
57,696
24
%
24
%
Non-GAAP Adjusted EBITDA
$
218,750
$
200,429
9
%
9
%
Adjusted EBITDA margin
37.4
%
34.9
%
Held for Sale or Sold:
Total Revenue, net
$
17,382
$
255,543
-93
%
-93
%
Non-GAAP Adjusted Operating (Loss) Income
$
(3,578
)
$
28,711
# #
Depreciation and amortization
-
3,437
# #
Non-GAAP Adjusted EBITDA
$
(3,578
)
$
32,148
# #
Adjusted EBITDA margin
-20.6
%
12.6
%
Corporate Expenses:
Non-GAAP Adjusted Corporate Expenses
$
(179,882
)
$
(185,456
)
3
%
3
%
Depreciation and amortization
13,924
22,434
38
%
38
%
Non-GAAP Adjusted EBITDA
$
(165,958
)
$
(163,022
)
-2
%
-2
%
Consolidated Results:
Revenue, net
$
1,677,609
$
1,872,987
-10
%
-10
%
Less: Held for Sale or Sold Segment (3)
(17,382
)
(255,543
)
-93
%
-93
%
Adjusted Revenue, net
$
1,660,227
$
1,617,444
3
%
3
%
Operating Income
$
221,409
$
52,261
# #
Adjustments:
Restructuring charges
25,561
63,041
59
%
59
%
Impairment of goodwill
-
108,449
# #
Held for Sale or Sold Segment Adjusted Operating Loss (Income) (3)
3,578
(28,711
)
# #
Non-GAAP Adjusted Operating Income
$
250,548
$
195,040
28
%
29
%
Adjusted Operating Income margin
15.1
%
12.1
%
Depreciation and amortization
147,126
176,989
17
%
17
%
Less: Held for Sale or Sold depreciation and amortization (3)
-
(3,437
)
# #
Non-GAAP Adjusted EBITDA
$
397,674
$
368,592
8
%
8
%
Adjusted EBITDA margin
24.0
%
22.8
%
# Variance greater than 100%
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1)
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands)
(unaudited)
April 30,
2025
2024
Assets:
Current assets
Cash and cash equivalents
$
85,882
$
83,249
Accounts receivable, net
228,410
224,198
Inventories, net
22,875
26,219
Prepaid expenses and other current assets
102,717
85,954
Current assets held-for-sale
-
34,422
Total current assets
439,884
454,042
Technology, property and equipment, net
162,125
192,438
Intangible assets, net
595,044
615,694
Goodwill
1,121,505
1,091,368
Operating lease right-of-use assets
66,128
69,074
Other non-current assets
306,780
283,719
Non-current assets held-for-sale
-
19,160
Total assets
$
2,691,466
$
2,725,495
Liabilities and shareholders' equity:
Current liabilities
Accounts payable
$
60,948
$
55,659
Accrued royalties
109,765
97,173
Short-term portion of long-term debt
10,000
7,500
Contract liabilities
462,693
483,778
Accrued employment costs
93,117
96,980
Short-term portion of operating lease liabilities
18,282
18,294
Other accrued liabilities
66,051
76,266
Current liabilities held-for-sale
-
37,632
Total current liabilities
820,856
873,282
Long-term debt
789,435
767,096
Accrued pension liability
71,899
70,832
Deferred income tax liabilities
105,145
97,186
Operating lease liabilities
81,482
94,386
Other long-term liabilities
70,443
71,760
Long-term liabilities held-for-sale
-
11,237
Total liabilities
1,939,260
1,985,779
Shareholders' equity
752,206
739,716
Total liabilities and shareholders' equity
$
2,691,466
$
2,725,495
Notes:
(1) The supplementary information included in this press release for April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
Expand
JOHN WILEY & SONS, INC.
SUPPLEMENTARY INFORMATION (1)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Year Ended
April 30,
2025
2024
Operating activities:
Net income (loss)
$
84,161
$
(200,319
)
Impairment of goodwill
-
108,449
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale
23,340
183,389
Amortization of intangible assets
51,822
55,994
Amortization of product development assets
16,610
22,835
Amortization of cloud computing arrangements
1,081
1,210
Depreciation and amortization of technology, property, and equipment
78,694
98,160
Other noncash charges
101,808
106,507
Net change in operating assets and liabilities
(154,925
)
(168,587
)
Net cash provided by operating activities
202,591
207,638
Investing activities:
Additions to technology, property, and equipment
(61,473
)
(76,080
)
Product development spending
(15,228
)
(17,262
)
Businesses acquired in purchase transactions, net of cash acquired
(3,602
)
(3,116
)
Net cash transferred related to the sale of businesses and assets
(7,642
)
(1,771
)
Acquisitions of publication rights and other
(6,073
)
(8,414
)
Net cash used in investing activities
(94,018
)
(106,643
)
Financing activities:
Net debt borrowings
13,509
27,767
Cash dividends
(76,101
)
(76,964
)
Purchases of treasury shares
(60,421
)
(45,050
)
Other
(2,317
)
(12,974
)
Net cash used in financing activities
(125,330
)
(107,221
)
Effects of exchange rate changes on cash, cash equivalents and restricted cash
3,146
(1,493
)
Change in cash, cash equivalents and restricted cash for period
(13,611
)
(7,719
)
Cash, cash equivalents and restricted cash - beginning
99,543
107,262
Cash, cash equivalents and restricted cash - ending
$
85,932
$
99,543
Year Ended
April 30,
2025
2024
Net cash provided by operating activities
$
202,591
$
207,638
Less: Additions to technology, property, and equipment
(61,473
)
(76,080
)
Less: Product development spending
(15,228
)
(17,262
)
Free cash flow less product development spending
$
125,890
$
114,296
Notes:
(1) The supplementary information included in this press release for the year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission.
(2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplemental information.
Expand
JOHN WILEY & SONS, INC.
EXPLANATION OF USAGE OF NON-GAAP PERFORMANCE MEASURES
In this earnings release and supplemental information, management may present the following non-GAAP performance measures:
Adjusted Earnings Per Share (Adjusted EPS);
Free Cash Flow less Product Development Spending;
Adjusted Revenue;
Adjusted Operating Income and margin;
Adjusted Income Before Taxes;
Adjusted Income Tax Provision;
Adjusted Effective Tax Rate;
EBITDA, Adjusted EBITDA and margin;
Organic revenue; and
Results on a constant currency basis.
Management uses these non-GAAP performance measures as supplemental indicators of our operating performance and financial position as well as for internal reporting and forecasting purposes, when publicly providing our outlook, to evaluate our performance and calculate incentive compensation.
We present these non-GAAP performance measures in addition to US GAAP financial results because we believe that these non-GAAP performance measures provide useful information to certain investors and financial analysts for operational trends and comparisons over time. The use of these non-GAAP performance measures may also provide a consistent basis to evaluate operating profitability and performance trends by excluding items that we do not consider to be controllable activities for this purpose.
The performance metric used by our chief operating decision maker to evaluate performance of our reportable segments is Adjusted Operating Income. We present both Adjusted Operating Income and Adjusted EBITDA for each of our reportable segments as we believe Adjusted EBITDA provides additional useful information to certain investors and financial analysts for operational trends and comparisons over time. It removes the impact of depreciation and amortization expense, as well as presents a consistent basis to evaluate operating profitability and compare our financial performance to that of our peer companies and competitors.
For example:
Adjusted EPS, Adjusted Revenue, Adjusted Operating Income, Adjusted Income Before Taxes, Adjusted Income Tax Provision, Adjusted Effective Tax Rate, Adjusted EBITDA, and organic revenue (excluding acquisitions) provide a more comparable basis to analyze operating results and earnings and are measures commonly used by shareholders to measure our performance.
Free Cash Flow less Product Development Spending helps assess our ability, over the long term, to create value for our shareholders as it represents cash available to repay debt, pay common stock dividends, and fund share repurchases and acquisitions.
Results on a constant currency basis remove distortion from the effects of foreign currency movements to provide better comparability of our business trends from period to period. We measure our performance excluding the impact of foreign currency (or at constant currency), which means that we apply the same foreign currency exchange rates for the current and equivalent prior period.
In addition, we have historically provided these or similar non-GAAP performance measures and understand that some investors and financial analysts find this information helpful in analyzing our operating margins and net income, and in comparing our financial performance to that of our peer companies and competitors. Based on interactions with investors, we also believe that our non-GAAP performance measures are regarded as useful to our investors as supplemental to our US GAAP financial results, and that there is no confusion regarding the adjustments or our operating performance to our investors due to the comprehensive nature of our disclosures.
We have not provided our 2026 outlook for the most directly comparable US GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with US GAAP.
Non-GAAP performance measures do not have standardized meanings prescribed by US GAAP and therefore may not be comparable to the calculation of similar measures used by other companies and should not be viewed as alternatives to measures of financial results under US GAAP. The adjusted metrics have limitations as analytical tools, and should not be considered in isolation from, or as a substitute for, US GAAP information. It does not purport to represent any similarly titled US GAAP information and is not an indicator of our performance under US GAAP. Non-GAAP financial metrics that we present may not be comparable with similarly titled measures used by others. Investors are cautioned against placing undue reliance on these non-GAAP measures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
‘Still Not a Bargain,' Says Top Investor About Nike Stock
'Just Do It,' goes the motto that Nike (NYSE:NKE) made a household catchphrase. With its branded 'Swoosh' and world-famous spokespeople, it is no stretch to argue that Nike helped to build the premium shoe market — one that grew by leaps and bounds earlier this decade. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Indeed, the COVID years saw a major spike in Nike's footwear sales – from $23.3 billion in 2020 to over $35 billion in 2023 – though growth has been slowing of late. Last year saw footwear revenues decrease slightly, and its share price has fallen almost 40% during the past twelve months. This week, Nike will be releasing its FQ4 2025 results, and consensus estimates are not exactly bullish. Analysts are expecting total revenues of $10.7 billion – down 15% year-over-year – while a projected EPS of $0.12 would represent an 89% decrease year-over-year. One top investor known by the pseudonym Stone Fox Capital thinks that the growing competition will continue to present stiff resistance going forward. 'Nike remains overvalued despite a significant price decline, with the market underestimating downside risks and ongoing competitive pressures,' explains the 5-star investor, who is among the top 3% of TipRanks' stock pros. The biggest challenge for Nike going forward will be the growing competition, asserts Stone Fox Capital, citing On Holding and HOKA as two of the biggest threats. For instance, ONON's On Running is expected to grow revenues by 40% this year. Still, NKE is trading 'at multiples above the market,' despite forecasts of stagnating growth going forward. Stone Fox Capital spots quite a disconnect – one that the market has yet to take fully into account. 'Nike should be viewed based on the readily available data of a massive athletic footwear company that hasn't grown in years facing immense competition,' adds Stone Fox Capital. Stone Fox Capital is urging investors to pay attention to upcoming guidance for the next quarter, which the investor predicts will be a 'horrible' forecast. Needless to say, Stone Fox Capital does not believe that 'Just Do It' is good advice for would-be investors at present. 'The stock might be down substantially from the all-time highs a few years ago, but Nike isn't actually trading like the business is under pressure,' concludes Stone Fox Capital, who rates NKE a Sell. (To watch Stone Fox Capital's track record, click here) Wall Street is overall positive when it comes to Nike, though not overwhelmingly. With 12 Buy and 11 Hold ratings, NKE is a consensus Moderate Buy. Its 12-month average price target of $71.24 has an upside of ~19%. (See NKE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
3 hours ago
- Yahoo
Better Cybersecurity Stock: CrowdStrike or SentinelOne?
CrowdStrike and SentinelOne have similar business models and offerings. CrowdStrike is much larger. SentinelOne trades at a steep discount to CrowdStrike. 10 stocks we like better than CrowdStrike › Artificial intelligence (AI) may have many benefits, but it's also making it easier for hackers, online criminals, and other digital malefactors to threaten businesses, and those threats are getting more potent. Keeping them at bay requires a lot of funds to be devoted to cybersecurity, making companies like CrowdStrike (NASDAQ: CRWD) and SentinelOne (NYSE: S) excellent investment opportunities. But is there an advantage to buying one over the other now? Both companies' base products are AI-powered protection platforms that analyze digital activity and learn to spot the threats among the normal activity. They deploy their software to network endpoints -- in other words, laptops, smartphones, and other devices that can access a client's internal network. By protecting these devices, companies make it harder for cyberattackers to gain access to their internal networks, where they might steal sensitive information, delete files, interfere with systems, or even lock them down with ransomware to extort payments from their victims. While endpoint protection is how both companies land clients, each bolsters its offerings with an array of other cybersecurity products that clients can use to create a protection suite tailored to their unique situations. Since these two direct competitors offer highly similar product types, it's hard to declare either a winner on this front from an investor perspective. Winner: Tie. From a sheer size perspective, CrowdStrike is the clear winner. During its fiscal 2026 first quarter, which ended April 30, CrowdStrike's annual recurring revenue (ARR) rose to $4.4 billion. SentinelOne's ARR of $948 million in its fiscal Q1 was less than a quarter of that. While size doesn't always matter, in this case, it does. Because so many more companies use CrowdStrike's platform, it's more likely that any given IT professional will have at least one contact already on its client list. If CrowdStrike is doing a great job with those clients, word will spread, and it will likely receive more serious consideration in future cybersecurity bidding processes. This advantage cannot be understated. Indeed, it's one of the reasons why CrowdStrike's growth has remained strong despite its size. Winner: CrowdStrike In terms of growth rates, SentinelOne is slightly outperforming CrowdStrike in this category. However, this should be no surprise because SentinelOne is a much smaller company. In fiscal Q1, SentinelOne's ARR rose 24% year over year, while CrowdStrike's increased 22% year over year. While I will give the point to SentinelOne, it's important to understand that CrowdStrike is growing from a much larger base than SentinelOne, making this close call all the more impressive for CrowdStrike. Winner: SentinelOne Due to its smaller size and focus on top-line growth, SentinelOne is far from profitable, while CrowdStrike has achieved intermittent profitability (although it reverted to a negative operating margin and a loss in its most recent quarter). SentinelOne is far from breaking even, but CrowdStrike was in this same position about five years ago. There's no reason not to expect SentinelOne to follow a similar path to profitability, but it will take some time. Meanwhile, CrowdStrike should eventually turn a profit again, as it has proven that it can do that. Winner: CrowdStrike CrowdStrike is leading this battle of the stocks so far, but SentinelOne is about to change the narrative with one jaw-dropping metric. CrowdStrike is the most popular cybersecurity stock in the market, and as a result, it has been bid up to expensive levels. From a price-to-sales (P/S) standpoint (the best metric to use to compare these companies since CrowdStrike flips between profitable and unprofitable, while SentinelOne is years away from profits), CrowdStrike has gotten far more expensive than SentinelOne over the past few years. CrowdStrike stock is now five times more expensive than SentinelOne, which is hard to believe, considering they compete in the same industry and are growing at nearly identical rates. This leads me to believe that CrowdStrike's stock has been overly hyped up while SentinelOne has been forgotten. While I'm OK with valuing CrowdStrike at a premium due to its market leadership position, this is far too great a premium to pay. SentinelOne is a dirt-cheap stock, and CrowdStrike is almost too expensive to consider. While I have been a long-term CrowdStrike bull, I'd be a bit cautious about buying the stock at its current lofty valuation. As a result, I think SentinelOne is the better cybersecurity investment right now. Before you buy stock in CrowdStrike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CrowdStrike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keithen Drury has positions in CrowdStrike. The Motley Fool has positions in and recommends CrowdStrike. The Motley Fool has a disclosure policy. Better Cybersecurity Stock: CrowdStrike or SentinelOne? was originally published by The Motley Fool Sign in to access your portfolio
Business Upturn
4 hours ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
